Brief: Lipigon Pharmaceuticals Q3 Operating Loss Widens To SEK 7.4 Mln
20/11/2025 07:12
Nov 20 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST: Q3 OPERATING LOSS SEK 7.4 MILLION VERSUS LOSS SEK 6.7 MILLION YEAR AGO Source text: ID:nBQNC4cL0 Further company coverage: LPGO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds